Does Jakafi (ruxolitinib) cause anemia?
Yes. Jakafi is known to cause anemia. In clinical use, lower hemoglobin levels and anemia are common side effects associated with ruxolitinib treatment [1].
Why would Jakafi lower hemoglobin?
Jakafi works by inhibiting JAK1/JAK2 signaling, which can affect blood cell production. That mechanism can lead to reduced red blood cell counts and hemoglobin, resulting in anemia [1].
How soon can anemia happen, and how is it monitored?
Anemia can develop during treatment and is typically monitored with regular complete blood counts (CBCs) and hemoglobin checks, with dose adjustments if levels drop too far [1].
What happens if anemia is severe?
If anemia becomes significant, clinicians may reduce the Jakafi dose or interrupt treatment until blood counts improve, based on CBC results and symptoms [1].
What should you watch for?
Patients often notice symptoms related to low red blood cells, such as fatigue, weakness, dizziness, or shortness of breath. Contact a clinician promptly if these occur, especially if they worsen during treatment [1].
Does stopping or reducing Jakafi reverse anemia?
Dose changes and treatment interruptions are used to manage anemia from Jakafi, and hemoglobin can improve when ruxolitinib exposure is reduced or paused [1].
Sources:
1. https://www.jakafi.com/ (Jakafi prescribing information and safety information, including anemia warnings)